| Literature DB >> 17950468 |
Francesca Gilli1, Fabiana Marnetto, Marzia Caldano, Paola Valentino, Letizia Granieri, Alessia Di Sapio, Marco Capobianco, Arianna Sala, Simona Malucchi, Ludwig Kappos, Raija L P Lindberg, Antonio Bertolotto.
Abstract
Many multiple sclerosis (MS) patients treated with interferon-beta (IFNbeta) develop anti-IFNbeta antibodies (BAbs), which can interfere with both in vitro and in vivo bioactivity of the injected cytokine. Objective of this study was to correlate these measures. Among the 256 enrolled patients, 11 (4.3%) showed a significant inhibition of the IFNbeta activity in vitro, but no measurable BAbs. As a whole, in vivo bioactivity was inhibited in 9/11 (82%) of these patients. A minority of IFNbeta treated patients have a non-antibody mediated neutralising activity, which competitively inhibits the bioactivity both in vitro and in vivo.Entities:
Mesh：
Substances：
Year: 2007 PMID： 17950468 DOI： 10.1016/j.jneuroim.2007.09.025
Source DB: PubMed Journal: J Neuroimmunol ISSN： 0165-5728 Impact factor: 3.478